A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Barth syndrome
  • Focus Therapeutic Use
  • Acronyms TAZPOWER
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 08 May 2017 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2017 Planned initiation date changed from 1 Mar 2017 to 1 May 2017.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top